Make an Inquiry
Accelerating Urticaria Drug Development

Urticaria presents significant therapeutic challenges due to its complex pathophysiology and the limited efficacy of current treatment options. Ace Therapeutics is a specialized partner in Urticaria drug development, dedicated to advancing innovative therapies for this underserved condition. Leveraging deep scientific expertise and state-of-the-art platforms, Ace Therapeutics delivers comprehensive preclinical solutions spanning target validation, lead optimization, pharmacology, toxicology, and IND-enabling studies. Our integrated approach ensures rigorous data generation and robust candidate selection, supported by a thorough understanding of Urticaria biology and translational science. Ace Therapeutics operates to the highest standards of regulatory compliance, facilitating efficient progression from discovery to clinical entry. By combining advanced technologies with a focused commitment to quality and scientific excellence, Ace Therapeutics accelerates the development of novel therapeutics, driving meaningful progress for patients affected by Urticaria.

What is UrticariaTargets for UrticariaDrug Discovery and Development ServicesWhy Choose Us

What is Urticaria

Urticaria, commonly referred to as hives, is a group of disorders characterized by the sudden onset of itchy, erythematous wheals and sometimes angioedema. The underlying etiology involves the activation and degranulation of skin mast cells, leading to the release of histamine and other inflammatory mediators that increase vascular permeability and cause the hallmark swelling and redness. Urticaria can be acute, often triggered by allergens such as foods, medications, or infections, or chronic, with symptoms persisting for six weeks or longer. Chronic urticaria may be spontaneous, frequently idiopathic or autoimmune in nature, or inducible, triggered by specific physical or environmental stimuli such as pressure, cold, or heat. Clinically, urticaria presents as transient, intensely pruritic wheals that typically resolve within 24 hours without residual skin changes. Angioedema may accompany or occur independently of wheals, occasionally affecting deeper tissues and posing a risk to the airway. Diagnosis is primarily clinical, based on the history and characteristic lesions, with laboratory investigations reserved for chronic or atypical cases. Treatment focuses on symptomatic relief, primarily using non-sedating second-generation antihistamines such as bilastine, rupatadine, levocetirizine, desloratadine, and fexofenadine. For refractory chronic cases, biologic agents like omalizumab or dupilumab may be indicated. The disease can significantly impact quality of life, emphasizing the importance of effective management.

Launched Drugs

Structure Generic Name CAS Registry Number Molecular Formula Molecular Weight
dupilumab (Rec INN; USAN); duplimab 1190264-60-8
img-202189-78-4-bilastine-rec-inn bilastine (Rec INN) 202189-78-4 C28 H37 N3 O3 463.612
omalizumab (Rec INN; USAN) 242138-07-4
img-158876-82-5-free-base182349-12-8-rupatadine-fumarate-prop-innm rupatadine fumarate (Prop INNM) 158876-82-5 (free base); 182349-12-8 C26 H26 Cl N3 . C4 H4 O4 532.03
img-130018-77-8-free-base130018-87-0---cetirizine-dihydrochloridelevocetirizine-dihydro (-)-cetirizine dihydrochloride; levocetirizine dihydrochloride (Prop INNM; USAN) 130018-77-8 (free base); 130018-87-0 C21 H25 Cl N2 O3 . 2 Cl H 461.81
img-100643-71-8-descarboethoxyloratadinedesloratadine-prop-inn-usa descarboethoxyloratadine; desloratadine (Prop INN; USAN) 100643-71-8 C19 H19 Cl N2 310.821
img-190786-44-8-bepotastine-besilate-prop-innm-usan bepotastine besilate (Prop INNM; USAN) 190786-44-8 C21 H25 Cl N2 O3 . C6 H6 O3 S 547.063
img-108612-45-9-mizolastine-rec-inn-ban mizolastine (Rec INN; BAN) 108612-45-9 C24 H25 F N6 O 432.493
img-113806-05-6-free-base140462-76-6-olopatadine-hydrochloride-rec-innm-usan olopatadine hydrochloride (Rec INNM; USAN) 113806-05-6 (free base); 140462-76-6 C21 H23 N O3 . Cl H 373.873
img-153439-40-8-fexofenadine-hydrochloride-prop-innm-usan-banmterf fexofenadine hydrochloride (Prop INNM; USAN; BANM); terfenadine carboxylate hydrochloride 153439-40-8 C32 H39 N O4 . Cl H 538.117

Learn More

Targets for Urticaria

Targets in Clinical or Later Phases of Development

Target Name Gene Symbol
5-hydroxytryptamine receptor 2B HTR2B
adrenoceptor alpha 1A ADRA1A
alpha1-Adrenoceptor (nonspecified subtype)
histamine receptor H1 HRH1
Histamine Receptor (HR) (nonspecified subtype)
IL-4 receptor
interleukin 13 IL13
immunoglobulin heavy constant epsilon IGHE
platelet activating factor receptor PTAFR
sigma non-opioid intracellular receptor 1 SIGMAR1

Urticaria pathogenesis is driven by a network of molecular targets that orchestrate immune activation, mast cell degranulation, and the resultant inflammatory response. Central among these are histamine receptors (HRH1, HRH4), which mediate the effects of histamine released from mast cells, leading to classic symptoms such as wheal, flare, and pruritus. Histidine decarboxylase (HDC) is key in histamine biosynthesis, while the immunoglobulin heavy constant epsilon (IGHE) encodes IgE, enabling mast cell sensitization and degranulation upon allergen exposure. Additional critical mediators include Bruton tyrosine kinase (BTK) and MAS related GPR family member X2 (MRGPRX2), which facilitate mast cell activation through IgE-dependent and independent pathways, respectively. Cytokines such as interleukin 4 (IL4) and interleukin 13 (IL13), along with Janus kinase 1 (JAK1), drive Th2 immune responses and promote IgE production, perpetuating the hypersensitivity cascade in urticaria.

Learn More

Drug Discovery and Development Services

In Vitro Efficacy Testing ServicesIn Vivo Model DevelopmentPK/PD Study ServicesIn Vivo Toxicity Assessment ServicesBiomarker Analysis Services
In Vitro Efficacy Testing Services

Online Inquiry

Our In Vitro Efficacy Testing Service accelerates urticaria drug discovery by providing comprehensive screening and characterization of candidate therapies. Utilizing advanced biochemical and cell-based assays, we evaluate compound potency, efficacy, and mechanism against key targets including histamine H1, BTK, JAK1, interleukins, and MRGPRX2. Methods such as chemiluminescence, HTRF, ELISA, and surface plasmon resonance enable precise quantification of pharmacological parameters (IC-50, EC-50, Kd, pKi). Our robust platforms deliver actionable data for lead optimization, supporting informed decision-making and efficient development of novel urticaria treatments targeting both allergic and non-histaminergic pathways.

Adrenoceptor Alpha 1A Bruton Tyrosine Kinase
Histamine Receptor H1 Interleukin 13
Interleukin 4 Janus Kinase 1
Mas Related Gpr Family Member X2 Melanocortin 1 Receptor

Learn More

Why Choose Us

At Ace Therapeutics, we are dedicated to advancing the field of Urticaria therapeutics through our specialized expertise in research and drug development. Our professional teams consist of highly qualified scientists and clinicians with extensive experience in Urticaria, ensuring that every project benefits from deep domain knowledge and the latest scientific insights. We utilize advanced technology platforms that enable us to efficiently and accurately conduct preclinical studies, providing our partners with reliable and actionable data. Ace Therapeutics has a proven track record of delivering high-quality preclinical drug development services, earning the trust of clients seeking dependable and innovative solutions. We adhere to the highest quality standards and maintain strict regulatory compliance, ensuring that our work meets both industry and governmental expectations. Above all, Ace Therapeutics is committed to making a meaningful impact in the treatment of Urticaria by supporting the development of new and effective therapeutics. Our passion for scientific excellence and patient outcomes drives us to be a trusted partner in your journey from discovery to preclinical success.

FAQs for Our Services

Q: What are the main preclinical research challenges specific to developing drugs for Urticaria?

A: One of the primary challenges in preclinical research for Urticaria is the lack of robust and predictive animal models that accurately recapitulate the complex pathophysiology of human urticaria, particularly chronic spontaneous urticaria (CSU). Additionally, the heterogeneity of disease mechanisms, including involvement of mast cells, basophils, and various immune mediators, complicates the selection of relevant biomarkers and endpoints. Our team addresses these challenges by leveraging the latest in vitro and in vivo models, incorporating patient-derived cells, and utilizing advanced analytics to ensure translational relevance.

Q: What are the key regulatory considerations for preclinical development of Urticaria therapeutics?

A: Regulatory agencies such as the FDA and EMA require comprehensive preclinical safety and efficacy data before progressing to clinical trials. For Urticaria, it is critical to demonstrate that candidate compounds do not exacerbate immune-mediated reactions or cause off-target immunosuppression. We support our clients by designing regulatory-compliant studies that include immunotoxicology, pharmacokinetics, and mechanistic investigations, and by providing guidance on IND-enabling study requirements specific to dermatological and immunological indications.

Q: What technical aspects should be considered when conducting preclinical research for Urticaria drug candidates?

A: Technical considerations include establishing validated assays for histamine release, mast cell degranulation, cytokine profiling, and skin wheal response. The selection of appropriate animal models, such as passive cutaneous anaphylaxis or humanized mouse models, is also crucial. Our laboratory offers state-of-the-art analytical platforms and custom assay development to ensure accurate assessment of drug mechanism and efficacy, tailored specifically for Urticaria research.

Q: What are the typical timeline and cost considerations for preclinical Urticaria drug development?

A: The preclinical phase for Urticaria drug development typically spans 12 to 24 months, depending on the complexity of the candidate and required studies. Costs can vary widely, ranging from $1 million to $5 million, influenced by the extent of in vivo efficacy, safety, and regulatory studies required. We provide detailed project planning and transparent cost estimates, and we work closely with clients to optimize study design and resource allocation to meet both scientific and budgetary goals.

Q: What are the main success factors in preclinical development of Urticaria therapeutics?

A: Key success factors include early identification of predictive biomarkers, selection of translationally relevant models, and robust demonstration of both efficacy and safety in preclinical studies. Close alignment with regulatory expectations and proactive risk mitigation strategies are also essential. Our company’s expertise in immunology, dermatology, and regulatory science enables us to guide clients through these critical steps, increasing the likelihood of successful advancement to clinical development.

Make an Inquiry
Important Links
Get in Touch with Us

Copyright © Ace Therapeutics. All rights reserved.